Equities research analysts predict that Compugen Ltd. (NASDAQ:CGEN) will report earnings of ($0.18) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Compugen’s earnings, with estimates ranging from ($0.20) to ($0.16). Compugen also reported earnings of ($0.18) per share during the same quarter last year. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 1st.
According to Zacks, analysts expect that Compugen will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.46) to ($0.42). For the next financial year, analysts forecast that the company will report earnings of ($0.84) per share, with EPS estimates ranging from ($1.00) to ($0.67). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Compugen.
Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Compugen from a “buy” rating to a “hold” rating in a research note on Monday, June 4th. ValuEngine raised shares of Compugen from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. CIBC assumed coverage on shares of Compugen in a research report on Thursday, March 29th. They set an “outperform” rating for the company. Finally, Oppenheimer assumed coverage on shares of Compugen in a research report on Thursday, March 29th. They set an “outperform” rating and a $9.00 price objective for the company.
Shares of Compugen traded down $0.10, hitting $3.75, on Wednesday, MarketBeat reports. The company’s stock had a trading volume of 422,200 shares, compared to its average volume of 266,928. Compugen has a fifty-two week low of $2.25 and a fifty-two week high of $5.00. The company has a market capitalization of $197.48 million, a PE ratio of -5.21 and a beta of 0.29.
A number of institutional investors and hedge funds have recently bought and sold shares of CGEN. Paloma Partners Management Co bought a new position in shares of Compugen in the fourth quarter worth about $105,000. ARK Investment Management LLC lifted its holdings in shares of Compugen by 95.9% in the fourth quarter. ARK Investment Management LLC now owns 2,253,416 shares of the biotechnology company’s stock worth $5,634,000 after acquiring an additional 1,103,384 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Compugen in the fourth quarter worth about $162,000. Anson Funds Management LP bought a new position in shares of Compugen in the fourth quarter worth about $281,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Compugen by 26.5% in the fourth quarter. Renaissance Technologies LLC now owns 340,008 shares of the biotechnology company’s stock worth $850,000 after acquiring an additional 71,308 shares during the last quarter. 21.23% of the stock is owned by institutional investors and hedge funds.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations.
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.